NCI-2024-06636

A Phase 1b/2 trial of Lamivudine in the Treatment of Relapsed/Refractory Solid Tumors Progression on Anti-PD-(L)1 blockade

In cancer treatment, Lamivudine is being explored for its potential to help fight cancer by improving the immune system's ability to attack tumors. While it is not typically used for cancer, some studies suggest that Lamivudine may have effects that could make immune therapies, like Anti-PD-(L)1 blockade, more effective. Anti-PD-(L)1 blockade therapies work by blocking a protein that prevents immune cells from attacking cancer cells, and Lamivudine might help enhance this process, especially in cancers that are not responding to other treatments. This is a phase 1b/2 trial.

Anti-PD-(L)1: Anti-PD-L1 antibodies are a type of immunotherapy used to treat cancer. They work by blocking the interaction between programmed cell death protein 1 ligand (PD-L1) on cancer cells and programmed cell death protein 1 (PD-1) on immune cells. This allows the immune system to recognize and attack cancer cells more effectively.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06494579

Clinical Trial Site: Sinai

To see all available clinical trials click here.